Conference Call with Hester Biosciences Management and Analysts on Q3FY23 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals firm Hester Biosciences announced Q3FY23 results: Standalone Q3FY23 results: Gross margins: There has been an improvement in the margins of health products in poultry healthcare and animal healthcare divisions. There has been a write-off of Rs 16 million of expired vaccine stocks in the poultry healthcare division. The overall impact has been a reduction of gross margins by 3% in Q3. PAT margin declined due to unrealized MTM losses of Rs 24.40 million on the translation of US $ loan, included in finance costs. Consolidated Q3FY23: Results also include operations of subsidiaries in Nepal and Tanzania. Hester Nepal had a turnover of Rs 52.62 million with an overall net profit of Rs 24.87 million during Q3FY23. Profit in Q3 grew with the improved profitability of Hester India, Hester Nepal and Hester’s share in the joint venture entity, Thrishool Exim Limited. In Hester Africa, market authorization has been received from Tanzania Medicines and Medical Devices Authority (TMDA) for two important ruminant vaccines, Lumpy Skin Disease and CBPP. Hester Nepal has received a manufacturing license and marketing authorization for two additional vaccines, Live LASMAS and Inactivated Coryza+. Result PDF
Pharmaceutical company Hester Biosciences announced Q2FY23 results: Q2FY23 & H1FY23: Standalone revenue is up by 27% and 6% for Q2FY23 and H1FY23 Consolidated revenue is up by 17% and 1% for Q2FY23 and H1FY23 Result PDF